Metagenomi Therapeutics (MGX) EBITDA Margin (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly EBITDA Margin of 1970.11% for Q1 2026, down 129601.0% year-over-year from N/an in Q1 2025, and down 216.21% quarter-over-quarter from 623.04% in Q4 2025.
Metagenomi Therapeutics (MGX) EBITDA Margin (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported EBITDA Margin for 4 consecutive years, with 1970.11% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 129601.0% year-over-year to 1970.11%; the TTM figure through Mar 2026 stood at 415.48% (down 22174.0% YoY), while the FY2025 annual figure was 380.85%, down 21085.0% from the prior year.
- EBITDA Margin fell to 1970.11% in Q1 2026 per MGX's latest filing, from 623.04% in the prior quarter.
- Across five years, EBITDA Margin topped out at 84.28% in Q2 2024 and bottomed at 1970.11% in Q1 2026.
- Historically, EBITDA Margin has averaged 403.12% across 4 years, with a median of 214.51% in 2024.
- Annual changes were most pronounced in 2024 — EBITDA Margin jumped 7416 bps — and 2026, when it sank 129601 bps.
- Metagenomi Therapeutics' EBITDA Margin stood at 162.88% in 2023, then plunged by 32 bps to 214.51% in 2024, then sank by 190 bps to 623.04% in 2025, then plunged by 216 bps to 1970.11% in 2026.
- Business Quant data shows MGX's EBITDA Margin at 1970.11% in Q1 2026, 623.04% in Q4 2025, and 263.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 19.75% |
| 10 | Metagenomi Therapeutics | 46.70 Mn | 46.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,970.11% |
| Dec 31, 2025 | -623.04% |
| Sep 30, 2025 | -263.76% |
| Jun 30, 2025 | -246.53% |
| Mar 31, 2025 | -674.10% |
| Dec 31, 2024 | -214.51% |
| Sep 30, 2024 | -194.40% |
| Jun 30, 2024 | -84.28% |
| Mar 31, 2024 | -260.17% |
| Dec 31, 2023 | -162.88% |
| Sep 30, 2023 | -181.15% |
| Jun 30, 2023 | -158.45% |
| Mar 31, 2023 | -207.21% |